Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,025,899

« Back to Dashboard
Patent 8,025,899 protects KALETRA and is included in one NDA. There have been two Paragraph IV challenges on Kaletra. There are six tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,025,899

Title:Solid pharmaceutical dosage form
Abstract: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
Inventor(s): Berndl; Gunther (Herxheim, DE), Rosenberg; Joerg (Ellerstadt, DE), Liepold; Bernd (Dossenheim, DE), Breitenbach; Joerg (Mannheim, DE), Reinhold; Ulrich (Heidelberg, DE), Alani; Laman (Foster City, CA), Ghosh; Soumojeet (Lansdale, PA)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/925,442
Patent Claim Types:
see list of patent claims
Dosage form; Formulation;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 196th percentile
Forward Citations: 5th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
lopinavir; ritonavir
TABLET;ORAL021906-002Nov 9, 2007RXNo8,025,899*PEDJun 14, 2028Y
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYes8,025,899*PEDJun 14, 2028Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.